Molecular pathways: Targeting the CXCR4-CXCL12 Axis-Untapped potential in the tumor microenvironment

Clinical Cancer Research

Volumn 21, Issue 19, 2015, Pages 4278-4285

  Scala, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ALX 0651; ANTINEOPLASTIC AGENT; BALIXAFORTIDE; BKT 140; BL 8040; BRUTON TYROSINE KINASE; BURIXAFOR; CARBOPLATIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRUTINIB; KRH 1636; LY 2510924; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MSX 122; NOX A 12; PLERIXAFOR; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR FOXP3; ULOCUPLUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; B CELL LEUKEMIA; BINDING AFFINITY; BREAST METASTASIS; CANCER THERAPY; CELL HOMING; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CXCR4 GENE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EWING SARCOMA; FOLLICULAR LYMPHOMA; GENE MUTATION; GLIOMA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CANCER; KIDNEY CARCINOMA; MANTLE CELL LYMPHOMA; METASTASIS POTENTIAL; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; SMALL CELL CARCINOMA; SMALL CELL LUNG CANCER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOKINE CXCL12; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84945431795     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0914     Document Type: Article

References (64)

1. Anders HJ, Romagnani P, Mantovani A. Pathomechanisms: homeostatic chemokines in health, tissue regeneration, and progressive diseases. Trends Mol Med 2014;20:154-65.
2. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011;11:597-606.
3. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-Transmembrane receptors. Nat Rev Drug Discov 2010;9: 373-86.
4. Bachelerie F, Graham GJ, Locati M, Mantovani A, Murphy PM, Nibbs R, et al. New nomenclature for atypical chemokine receptors. Nat Immunol 2014;15:207-8.
5. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature 2009;459:356-63.
6. Roland J, Murphy BJ, Ahr B, Robert-Hebmann V, Delauzun V, Nye KE, et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood 2003;101:399-406.
7. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997;16:6996-7007.
8. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010;16:2927-31.
9. Cheng ZJ, Zhao J, Sun Y, Hu W, Wu YL, Cen B, et al. Beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem 2000;275:2479-85.
10. Munk R, Ghosh P, Ghosh MC, Saito T, Xu M, Carter A, et al. Involvement of mTOR in CXCL12 mediated T cell signaling and migration. PLoS ONE 2011;6:e24667.
11. Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targetingmammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem 2012;287:12132-41.
12. Hashimoto I, Koizumi K, Tatematsu M, Minami T, Cho S, Takeno N, et al. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer 2008;44:1022-9.
13. Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, et al. Stromal cell-derived factor 1alpha mediates resistance to mTORdirected therapy in pancreatic cancer. Neoplasia 2012;14:690-701.
14. Ierano C, Santagata S, Napolitano M, Guardia F, Grimaldi A, Antignani E, et al. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis 2014;5:e1310.
15. Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatmentwith the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013;122:2412-24.
16. Marchese A. Endocytic trafficking of chemokine receptors. Curr Opin Cell Biol 2014;27:72-7.
17. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005;280:35760-6.
18. Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O, et al. Chemokine receptor trio: CXCR3, CXCR4, and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev 2013;24:41-9.
19. Scala S, Giuliano P, Ascierto PA, Ierano C, Franco R, Napolitano M, et al. Humanmelanoma metastases express functional CXCR4. Clin Cancer Res 2006;12:2427-33.
20. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655-64.
21. Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 2012;26: 34-53.
22. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-102.
23. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003;34:70-4.
24. Kallikourdis M, Trovato AE, Anselmi F, Sarukhan A, Roselli G, Tassone L, et al. The CXCR4 mutations in WHIMsyndrome impair the stability of the T-cell immunologic synapse. Blood 2013;122:666-73.
25. McDermott DH, LiuQ, Ulrick J, Kwatemaa N, Anaya-O'Brien S, Penzak SR, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011;118:4957-62.
26. McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O'Brien S, Ulrick J, et al. A phase 1 clinical trial of long-Term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 2014;123:2308-16.
27. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somaticmutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014;123: 2791-6.
28. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4: 540-50.
29. D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, et al. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. Int J Cancer 2014;135:379-90.
30. D'Alterio C, Cindolo L, Portella L, PolimenoM, Consales C, Riccio A, et al. Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010;9:4492-500.
31. Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, et al. CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. Cell Mol Immunol 2015;12:474-82.
32. Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage IIIII colorectal cancer patients. Clin Cancer Res 2006;12:2795-803.
33. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005;11:1835-41.
34. Miao Z, Luker KE, Summers BC, Berahovich R, BhojaniMS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007;104:15735-40.
35. Hattermann K, Held-Feindt J, Lucius R, Muerkoster SS, Penfold ME, Schall TJ, et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010;70: 3299-308.
36. Liu Y, Carson-Walter E, Walter KA. Chemokine receptor CXCR7 is a functional receptor for CXCL12 in brain endothelial cells. PLoS ONE 2014;9:e103938.
37. Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, et al. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther 2014;13:1155-69.
38. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011;17:2074-80.
39. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52.
40. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in animmunocompetent mouse model of ovarian cancer. Cancer Res 2011;71:5522-34.
41. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013;110:20212-7.
42. Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, et al. CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-Treated HCC in mice. Hepatology 2015;61:1591-602.
43. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
44. Joyce JA, Fearon DT. T-cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80.
45. Portella L, Vitale R, De Luca S, D'Alterio C, Ierano C, Napolitano M, et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS ONE 2013;8:e74548.
46. Amodeo P, Vitale R, De Luca S, Scala S, Castello G, Siani A, inventors. Cyclic peptides binding CXCR4 receptor and relative medical and diagnostic uses. Europe patent EP 2528936. 2014 Oct 22.
47. Wang L, Liu Y, Han R, Beier UH, Bhatti TR, Akimova T, et al. FOXP3+ regulatory T-cell development and function require histone/protein deacetylase 3. J Clin Invest 2015;125:1111-23.
48. Ierano C, Basseville A, To KK, Zhan Z, Robey RW, Wilkerson J, et al. Histone deacetylase inhibitors induceCXCR4mRNAbut antagonize CXCR4 migration. Cancer Biol Ther 2013;14:175-83.
49. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-62.
50. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, RosenbaumJS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009;75:1240-7.
51. GalskyMD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S, et al. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res 2014;20:3581-8.
52. Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 2007;25:2158-66.
53. Abraham M, Beider K, Wald H, Weiss ID, Zipori D, Galun E, et al. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 2009;23:1378-88.
54. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, et al. T140 analogs as CXCR4 antagonists identified as antimetastatic agents in the treatment of breast cancer. FEBS Lett 2003;550: 79-83.
55. Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, et al. The highaffinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res 2014;20:469-79.
56. Spigel DR, Weaver RW, McCleodM, Hamid O, Stille JR, Polzer J, et al. Phase II study of carboplatin/etoposide plus LY2510924, a CXCR4 peptide antagonist, versus carboplatin/etoposide in patients with extensive-stage small cell lung cancer (SCLC). Ann Oncol 2014;25:iv511-6.
57. Wong D, Kandagatla P, Korz W, Chinni SR. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol 2014;14:12.
58. Hotte SJ, Hirte HW, Moretto P, Iacobucci A, Wong D, Korz W, et al. Final results of a phase I/II study of CTCE-9908, a novel anticancer agent that inhibitsCXCR4, in patients with advanced solid cancers. Eur J Cancer Suppl 2008;6:127.
59. Crump MP, Elisseeva E, Gong J, Clark-Lewis I, Sykes BD. Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-Terminal segment (1-10). FEBS Lett 2001;489:171-5.
60. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997;277: 1656-9.
61. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120:694-705.
62. Wong D, Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 2008;14:7975-80.
63. Faber A, Roderburg C, Wein F, Saffrich R, Seckinger A, Horsch K, et al. The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J Biomed Biotechnol 2007;2007: 26065.
64. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 2003;100:4185-90.